This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Using RP-VITA, A Physician Communicates With His Patient Remotely. (Photo: Business Wire)

iRobot Corp. (NASDAQ: IRBT), a leader in delivering robotic solutions, announced that the RP-VITA Remote Presence Robot has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in hospitals. RP-VITA is the first autonomous navigation remote presence robot to receive FDA clearance.

Using RP-VITA, a physician communicates with his patient remotely. (Photo: Business Wire)

Using RP-VITA, a physician communicates with his patient remotely. (Photo: Business Wire)

RP-VITA is a joint effort between two industry leaders, iRobot and InTouch Health. The robot combines the latest in autonomous navigation and mobility technologies developed by iRobot with state-of-the-art telemedicine and electronic health record integration developed by InTouch Health. RP-VITA allows remote doctor-to-patient consults, ensuring that the physician is in the right place at the right time and has access to the necessary clinical information to take immediate action. The robot has unprecedented ease of use. It maps its own environment and uses an array of sophisticated sensors to autonomously move about a busy space without interfering with people or other objects. Using an intuitive iPad® interface, a doctor can visit a patient, and communicate with hospital staff and patients with a single click, regardless of their location.

The FDA clearance specifies that RP-VITA can be used for active patient monitoring in pre-operative, peri-operative and post-surgical settings, including cardiovascular, neurological, prenatal, psychological and critical care assessments and examinations.

RP-VITA is being sold into the healthcare market by InTouch Health as its new flagship remote presence device. iRobot will continue to explore adjacent market opportunities for robots like RP-VITA and the iRobot Ava™ mobile robotics platform.

“FDA clearance of a robot that can move safely and independently through a fast-paced, chaotic and demanding hospital environment is a significant technological milestone for the robotics and healthcare industries,” said Colin Angle, chairman and CEO of iRobot. “There are very few environments as difficult to maneuver as that of a busy ICU or emergency department. Having crossed this technology threshold, the potential for self-navigating robots in other markets, and for new applications, is virtually limitless.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs